SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
The demand in Africa for COVID-19 vaccines has declined
Global Phase-3 study initiation expected in the second half of 2024
KRKA holds 51% and Laurus Labs holds 49% shareholding
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
_256_384.jpg)
This facility manufactures APIs & formulations of oncology and non-oncology products.
Sun Pharma's Dadra facility receives OAI status from US FDA
Subscribe To Our Newsletter & Stay Updated
